ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro

References

• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med20103622260227020525995
   PubMed Web of Science ®Google Scholar
• KantarjianHMHochhausASaglioGNilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialLancet Oncol20111284185121856226
   PubMed Web of Science ®Google Scholar
• DohseMScharenbergCShuklaSComparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinibDrug Metab Dispos2010381371138020423956
   PubMed Web of Science ®Google Scholar
• HegedusCOzvegy-LaczkaCApátiAInteraction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological propertiesBr J Pharmacol20091581153116419785662
   PubMed Web of Science ®Google Scholar
• HiwaseDKSaundersVHewettDDasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsClin Cancer Res2008143881388818559609
   PubMed Web of Science ®Google Scholar
• MlejnekPDolezelPFaberEKosztyuPInteractions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cellsAnn Hematol20119083784221225261
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGJohnsonJRApproval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemiaClin Cancer Res2002893594212006504
   PubMed Web of Science ®Google Scholar
• GreenHSkoglundKRommelFMirghaniRALotfiKCYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activityEur J Clin Pharmacol20106638338620054526
   PubMed Web of Science ®Google Scholar
• ThiebautFTsuruoTHamadaHGottesmanMMPastanIWillinghamMCCellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissuesProc Natl Acad Sci U S A198784773577382444983
   PubMed Web of Science ®Google Scholar
• ThomasJWangLClarkREPirmohamedMActive transport of imatinib into and out of cells: implications for drug resistanceBlood20041043739374515315971
   PubMed Web of Science ®Google Scholar
• JiangXZhaoYSmithCChronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapiesLeukemia20072192693517330101
   PubMed Web of Science ®Google Scholar
• RacilZRazgaFPolakovaKMAssessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell typesLeuk Lymphoma20115233133421133723
   PubMed Web of Science ®Google Scholar
• LarsonRADrukerBJGuilhotFImatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyBlood20081114022402818256322
   PubMed Web of Science ®Google Scholar
• PicardSTitierKEtienneGTrough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood20071093496349917192396
   PubMed Web of Science ®Google Scholar
• WhiteDLRadichJSoveriniSChronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibHaematologica20129790791422207690
   PubMed Web of Science ®Google Scholar
• CascorbiIP-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variationsHandb Exp Pharmacol201120126128321103972
   PubMedGoogle Scholar
• KroetzDLPauli-MagnusCHodgesLMSequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) genePharmacogenetics20031348149412893986
   PubMedGoogle Scholar
• DeenikWvan der HoltBJanssenJJPolymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving highdose imatinibBlood201011661446145 author reply 6145–614621183698
   PubMed Web of Science ®Google Scholar
• DulucqSBouchetSTurcqBMultidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood20081122024202718524988
   PubMed Web of Science ®Google Scholar
• NiLNLiJYMiaoKRMultidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemiaMed Oncol20112826526920204543
   PubMed Web of Science ®Google Scholar
• GurneyHWongMBalleineRLImatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotypeClin Pharmacol Ther200782334017495881
   PubMed Web of Science ®Google Scholar
• MarinDBazeosAMahonFXAdherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibJ Clin Oncol2010282381238820385986
   PubMed Web of Science ®Google Scholar
• TakahashiNMiuraMScottSAInfluence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemiaJ Hum Genet20105573173720720558
   PubMed Web of Science ®Google Scholar
• KimDHSriharshaLXuWClinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemiaClin Cancer Res2009154750475819584153
   PubMed Web of Science ®Google Scholar
• SeongSJLimMSohnSKInfluence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patientsAnn Oncol20122475676023117072
   PubMed Web of Science ®Google Scholar
• GréenHFalkIJLotfiKAssociation of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotypePharmacogenomics J20121211111820938465
   PubMed Web of Science ®Google Scholar
• GreenHSoderkvistPRosenbergPHorvathGPetersonCABCB1 G1199A polymorphism and ovarian cancer response to paclitaxelJ Pharm Sci2008972045204817828752
   PubMed Web of Science ®Google Scholar
• CascorbiIGerloffTJohneAFrequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjectsClin Pharmacol Ther20016916917411240981
   PubMed Web of Science ®Google Scholar
• DeKoterRPSchweitzerBLKamathMBRegulation of the interleukin-7 receptor alpha promoter by the Ets transcription factors PU.1 and GA-binding protein in developing B cellsJ Biol Chem2007282141941420417392277
   PubMed Web of Science ®Google Scholar
• MosmannTRapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assaysJ Immunol Methods19836555636606682
   PubMed Web of Science ®Google Scholar
• MarzoliniCPausEBuclinTKimRBPolymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevanceClin Pharmacol Ther200475133314749689
   PubMed Web of Science ®Google Scholar
• ChristopherLJCuiDWuCMetabolism and disposition of dasatinib after oral administration to humansDrug Metab Dispos2008361357136418420784
   PubMed Web of Science ®Google Scholar
• NovartisNDA 22-068: Clinical pharmacology and biopharmaceutics review2006 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068s000_ClinPharmR.pdfAccessed April 29, 2013
   Google Scholar
• HsyuPHMouldDRUptonRNAmanteaMPharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemiaCancer Chemother Pharmacol20137120921823070145
   PubMed Web of Science ®Google Scholar
• Kimchi-SarfatyCGribarJJGottesmanMMFunctional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression systemMol Pharmacol2002621612065748
   PubMed Web of Science ®Google Scholar
• MoritaNYasumoriTNakayamaKHuman MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activitiesBiochem Pharmacol2003651843185212781336
   PubMed Web of Science ®Google Scholar
• HoffmeyerSBurkOvon RichterOFunctional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProc Natl Acad Sci U S A2000973473347810716719
   PubMed Web of Science ®Google Scholar
• WacherVJWuCYBenetLZOverlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapyMol Carcinog1995131291347619215
   PubMed Web of Science ®Google Scholar
• van ErpNPGelderblomHGuchelaarHJClinical pharmacokinetics of tyrosine kinase inhibitorsCancer Treat Rev20093569270619733976
   PubMed Web of Science ®Google Scholar
• AbbasRHugBALeisterCBurnsJSonnichsenDEffect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjectsJ Clin Pharmacol2011511721172721148045
   PubMed Web of Science ®Google Scholar
• WhiteDLSaundersVADangPOCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinibBlood200610869770416597591
   PubMed Web of Science ®Google Scholar
• MaliepaardMSchefferGLFaneyteIFSubcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissuesCancer Res2001613458346411309308
   PubMed Web of Science ®Google Scholar
• JordanidesNEJorgensenHGHolyoakeTLMountfordJCFunctional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylateBlood20061081370137316627755
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information 1000 Genomes Browser version 3.0 Available from: http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/Accessed August 1, 2013
   Google Scholar